The Filing Desk

Autolus Therapeutics

AUTL · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AUTL · Last close · November 19, 2026
$0.98
Value Autolus Therapeutics yourself

Autolus Therapeutics' revenue rose 644.9% to $75 million in fiscal 2025. Its operating margin was −358.9%, up from −2,385.6% a year earlier. Free cash flow was −$303 million. The diluted share count rose 4.3%.

Autolus Therapeutics plc Latest fiscal year ended December 31, 2025 10-K filed March 27, 2026 · 0001730463-26-000038 Updated
Revenue
$75M
644.9%
Operating margin
−358.9%
2026.8 pts
Net income
−$288M
 
Free cash flow
−$303M
 
Return on equity
−95.0%
13.1 pts
Market cap
$261M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Autolus Therapeutics does

Autolus is an early commercial-stage biopharmaceutical company. It develops, makes and delivers T cell therapies, in which a patient's own immune cells are engineered to find and destroy cancer cells, and it is also testing them against autoimmune diseases.

Its first product, AUCATZYL (obe-cel), is a CAR T cell therapy for adults whose B-cell precursor acute lymphoblastic leukemia, a fast-growing blood cancer, has come back or not responded to treatment. The US Food and Drug Administration approved it in November 2024, and the first US sale came in January 2025. It has also been cleared in the United Kingdom and the European Union, and launched in the UK in January 2026. The company says its EU launch is on hold and it expects no EU sales of AUCATZYL in 2026.

Autolus makes AUCATZYL at its own site, the Nucleus, in Stevenage, UK. Cardinal Health is its commercial distribution partner in the US. It is also testing obe-cel in children with leukemia and lymphoma, and in people with severe lupus.

Its biggest risks, as it describes them

  • Losses since it began, and the need for more funding to sell AUCATZYL and develop other candidates.
  • AUCATZYL may not win enough acceptance from doctors, patients and insurers.
  • Competition from CD19-targeted CAR T therapies from Novartis, Gilead and BMS.
  • Obligations under license and collaboration deals, including with Blackstone, that limit its flexibility.
  • Whether insurers will cover and reimburse its therapies at adequate rates.
From Autolus Therapeutics's annual report on Form 10-K, filed March 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Autolus Therapeutics lost money in fiscal 2025: a net loss of $288 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments310382240588301
Debt incl. finance leases00000
Net debt (negative means net cash)−310−382−240−588−301
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−127.7x−16.1x−4.0x−26.0x−7.4x
Current ratio12.2x9.2x6.2x10.9x5.9x
Quick ratio12.2x9.2x6.2x10.8x5.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Autolus Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Autolus Therapeutics shares on the open market, and 1 insider sold $15,708.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Cintia PiccinaU.S. CCO & Country Gen ManagerSold6,713$2.34$15,708Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—3 of 93 of 9
Rule of 40—−1,760.4%243.5%
Altman Z''−6.37−0.36−6.27
Accruals ratio−14.5%−2.5%−0.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose—FailFail
Revenue rose relative to assets—PassPass
F-score—3 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Autolus Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Autolus TherapeuticsFY25644.9%−358.9%−401.4%——3
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
CytomX TherapeuticsFY25−44.8%−29.4%−99.5%———Compare
CellectisFY2575.8%−45.3%−57.2%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1213———21075
Revenue growth—39.7%−16.9%106.7%————496.0%644.9%
Gross profit———————2−1−21
Research and development101636105135111117130138118
Operating income—−23−58−146−168−141−143−180−241−270
Net income−12−20−45−124−142−142−149−208−221−288
Diluted EPS (US$)−1.26−1.43−1.42−2.88−2.76−1.97−1.57−1.20−0.86−1.08
Diluted shares (millions)10143243527295174255266
Cash flow
Cash from operations−10−16−32−102−118−118−112−146−206−284
Capital expenditure2391815911112219
Free cash flow−12−19−41−120−132−127−123−157−228−303
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation23730201012111614
Balance sheet at fiscal year end
Cash and short-term investments28137247211154310382240588301
Debt incl. finance leases—100000000
Total assets—149273304294406490375783589
Total liabilities—618498492192264355411
Shareholders' equity31143256255210313299112427178
Margins and ratios
Gross margin———————100.0%−12.5%−27.8%
Operating margin—−1,383.2%−4,089.1%−5,022.8%———−10,583.1%−2,385.6%−358.9%
Net margin−1,035.5%−1,165.2%−3,180.6%−4,258.9%———−12,272.3%−2,180.4%−381.4%
Free cash flow margin−965.7%−1,136.2%−2,889.6%−4,120.5%———−9,221.0%−2,256.4%−401.4%
Rule of 40 (growth + FCF margin)—−1,096.5%−2,906.4%−4,013.8%————−1,760.4%243.5%
Return on capital————−267.4%—————
Return on equity——−22.5%−48.5%−61.1%−54.3%−48.6%−101.6%−81.9%−95.0%
Return on assets——−21.2%−43.0%−47.5%−40.6%−33.2%−48.1%−38.1%−41.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Autolus Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Autolus Therapeutics.